Advanced ventricular assist device with pulse augmentation and automatic regurgitant-flow shut-off

Fukamachi, Kiyotaka; Horvath, David J.; Byram, Nicole; Sunagawa, Gengo; Karimov, Jamshid H.; Moazami, Nader

doi:10.1016/j.healun.2016.07.019

Cited by 19 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pump also showed significantly less blood trauma and markedly lower shear stress than current CF LVADs. We are now developing an advanced ventricular assist device, which is able to generate greater levels of pulsatility and possessing a shut‐off feature with the additional ability to modulate the axial position of a rotor by pressure differences in the inlet and outlet . In CF TAHs (CFTAHs), unlike LVAD support, the pressure waveform is completely flat in CF mode, as the entire heart must be removed to implant the pump.…”

Section: New Durable Mcs Devices Generating Pfmentioning

confidence: 99%

“…We are now developing an advanced ventricular assist device, which is able to generate greater levels of pulsatility and possessing a shut-off feature with the additional ability to modulate the axial position of a rotor by pressure differences in the inlet and outlet. 47 In CF TAHs (CFTAHs), unlike LVAD support, the pressure waveform is completely flat in CF mode, as the entire heart must be removed to implant the pump. Our CFTAH under development has a speed modulation mode, and the systemic and pulmonary arterial pulse pressures are increased to 12.0 and 12.3 mm Hg (±15% modulation) and to 15.9 and 15.7 mm Hg (±25% modulation), respectively.…”

Section: Generating Pfmentioning

confidence: 99%

See 1 more Smart Citation

Acute and chronic effects of continuous‐flow support and pulsatile‐flow support

2019

Self Cite

View full text Add to dashboard Cite

Section: New Durable Mcs Devices Generating Pfmentioning

confidence: 99%

Section: Generating Pfmentioning

confidence: 99%

Acute and chronic effects of continuous‐flow support and pulsatile‐flow support

2019

Self Cite

View full text Add to dashboard Cite

“…We previously reported on the pulse augmentation and regurgitant flow shut‐off features of the first working prototype (AVα) of the Advanced VAD . Since then, we have applied design modifications to enhance these features.…”

Section: Introductionmentioning

confidence: 99%

The design modification of advanced ventricular assist device to enhance pulse augmentation and regurgitant flow shut‐off

et al. 2019

Self Cite

View full text Add to dashboard Cite

The new Advanced ventricular assist device (Advanced VAD) has many features such as improving pulsatility and preventing regurgitant flow during pump stoppage. The purpose of this study was to evaluate the effects of design modifications of the Advanced VAD on these features in vitro. Bench testing of four versions of the Advanced VAD was performed on a static or pulsatile mock loop with a pneumatic device. After pump performance was evaluated, each pump was run at 3000 rpm to evaluate pulse augmentation, then was stopped to assess regurgitant flow through the pump. There was no significant difference in pump performance between the pump models. The average pulse pressure in the pulsatile mock loop was 23.0, 34.0, 39.3, 33.8, and 37.3 mm Hg without pump, with AV010, AV020 3S, AV020 6S, and AV020 RC, respectively. The pulse augmentation factor was 48%, 71%, 47%, and 62% with AV010, AV020 3S, AV020 6S, and AV020 RC, respectively. In the pump stop test, regurgitant flow was −0.60 ± 0.70, −0.13 ± 0.57, −0.14 ± 0.09, and −0.18 ± 0.06 L/min in AV010, AV020 3S, AV020 6S, and AV020 RC, respectively. In conclusion, by modifying the design of the Advanced VAD, we successfully showed the improved pulsatility augmentation and regurgitant flow shut‐off features.

show abstract

“…New MCS technologies continue to emerge, with the hope that they will overcome these device‐related complications and improve clinical outcomes. In our institution, we are developing technologies that contain some advanced features, such as an automated regulation, available with a continuous flow total artificial heart (CFTAH) and the advanced ventricular assist device intended for biventricular heart failure support …”

Section: Introductionmentioning

confidence: 99%

“…In our institution, we are developing technologies that contain some advanced features, such as an automated regulation, available with a continuous flow total artificial heart (CFTAH) and the advanced ventricular assist device intended for biventricular heart failure support. 2,3 In developing and evaluating MCS devices, in vitro testing plays an important role in addition to animal experiments and clinical trials. In vitro (so-called circulatory mock loop) is a physical model of a circulation simulator, and usually contains compliance tanks, valves, and tubing to mimic the resistances, compliances, and overall characteristics of the cardiovascular system.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Cleveland Clinic continuous‐flow total artificial heart performance using the Virtual Mock Loop: Comparison with an in vivo study

Miyamoto

Horvath²,

Horvath³

et al. 2019

Artificial Organs

Self Cite

View full text Add to dashboard Cite

The Virtual Mock Loop (VML) is a mathematical model designed to simulate mechanism of the human cardiovascular system interacting with mechanical circulatory support devices. Here, we aimed to mimic the hemodynamic performance of Cleveland Clinic’s self‐regulating continuous‐flow total artificial heart (CFTAH) via VML and evaluate the accuracy of the VML compared with an in vivo acute animal study. The VML reproduced 124 hemodynamic conditions from three acute in vivo experiments in calves. Systemic/pulmonary vascular resistances, pump rotational speed, pulsatility, and pulse rate were set for the VML from in vivo data. We compared outputs (pump flow, left and right pump pressure rises, and atrial pressure difference) between the two systems. The pump performance curves all fell in the designed range. There was a strong correlation between the VML and the in vivo study in the left pump flow (r2 = 0.84) and pressure rise (r2 = 0.80), and a moderate correlation in right pressure rise (r2 = 0.52) and atrial pressure difference (r2 = 0.59). Although there is room for improvement in simulating right‐sided pump performance of self‐regulating CFTAH, the VML acceptably simulated the hemodynamics observed in an in vivo study. These results indicate that pump flow and pressure rise can be estimated from vascular resistances and pump settings.

show abstract

Advanced ventricular assist device with pulse augmentation and automatic regurgitant-flow shut-off

Cited by 19 publications

References 5 publications

Acute and chronic effects of continuous‐flow support and pulsatile‐flow support

Acute and chronic effects of continuous‐flow support and pulsatile‐flow support

The design modification of advanced ventricular assist device to enhance pulse augmentation and regurgitant flow shut‐off

Analysis of Cleveland Clinic continuous‐flow total artificial heart performance using the Virtual Mock Loop: Comparison with an in vivo study

Contact Info

Product

Resources

About